3097985-19-5
Chemical Structure
ACBI-4
- CAS No.: 3097985-19-5
- Formula:C50H63N15O4S
- Molecular Weight:970.20
IUPAC Name: (2S,4R)-1-((S)-2-((S)-5-(3-((S)-4-(4-(5-((S)-2-amino-3-cyano-4-methyl-4,5,6,7-tetrahydrobenzo[b]thiophen-4-yl)-1,2,4-oxadiazol-3-yl)pyrimidin-2-yl)-3-methyl-1,4-diazepan-1-yl)propyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1-yl)-3-methylbutanoyl)-4-hydroxy-N-((1-methyl-1H-indazol-6-yl)methyl)pyrrolidine-2-carboxamide
InChIKey: BLVMQMPRWNDEDM-ZSNUXIQQSA-N
SMILES: CC([C@H](N1N=NC2=C1CC[C@H](CCCN3C[C@@H](N(CCC3)C4=NC(C5=NOC([C@@]6(C7=C(CCC6)SC(N)=C7C#N)C)=N5)=CC=N4)C)C2)C(N8C[C@@H](C[C@H]8C(NCC9=CC=C%10C(N(N=C%10)C)=C9)=O)O)=O)C
Biological Activity: ACBI-4 is a selective GTP-loaded active state of KRAS (KRAS(on)) PROTAC degrader, with Kd values of 141 nM against KRASG12R. ACBI-4 forms a stable ternary complex with VHL, triggering ubiquitination and KRAS degradation via the ubiquitin-proteasome system. ACBI-4 induces antiproliferative effects in KRAS mutant-driven cancer cells. ACBI-4 can be used for the research of KRAS mutant-driven cancer[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ACBI-4 | 98.01% | ACBI-4 is a selective GTP-loaded active state of KRAS (KRAS(on)) PROTAC degrader, with Kd values of 141 nM against KRASG12R. ACBI-4 forms a stable ternary complex with VHL, triggering ubiquitination and KRAS degradation via the ubiquitin-proteasome system. ACBI-4 induces antiproliferative effects in KRAS mutant-driven cancer cells. ACBI-4 can be used for the research of KRAS mutant-driven cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
